company background image
IBIO logo

iBio NYSEAM:IBIO Stock Report

Last Price

US$1.72

Market Cap

US$14.8m

7D

-14.9%

1Y

-93.4%

Updated

20 Apr, 2024

Data

Company Financials

IBIO Stock Overview

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States.

IBIO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

iBio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for iBio
Historical stock prices
Current Share PriceUS$1.72
52 Week HighUS$26.20
52 Week LowUS$1.02
Beta-3.52
1 Month Change59.26%
3 Month Change62.56%
1 Year Change-93.38%
3 Year Change-99.74%
5 Year Change-99.58%
Change since IPO-99.96%

Recent News & Updates

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07
iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Shareholder Returns

IBIOUS BiotechsUS Market
7D-14.9%-4.7%-3.7%
1Y-93.4%-2.7%20.2%

Return vs Industry: IBIO underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: IBIO underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is IBIO's price volatile compared to industry and market?
IBIO volatility
IBIO Average Weekly Movement55.8%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: IBIO's share price has been volatile over the past 3 months.

Volatility Over Time: IBIO's weekly volatility has increased from 31% to 56% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200826Martin Brennerwww.ibioinc.com

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever.

iBio, Inc. Fundamentals Summary

How do iBio's earnings and revenue compare to its market cap?
IBIO fundamental statistics
Market capUS$14.81m
Earnings (TTM)-US$20.77m
Revenue (TTM)US$50.00k

296.2x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IBIO income statement (TTM)
RevenueUS$50.00k
Cost of RevenueUS$0
Gross ProfitUS$50.00k
Other ExpensesUS$20.82m
Earnings-US$20.77m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.41
Gross Margin100.00%
Net Profit Margin-41,546.00%
Debt/Equity Ratio142.8%

How did IBIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.